Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome
Status:
Terminated
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The study purpose is to determine the hypolipidemic effect of Alirocumab co-administered with
atorvastatin on levels of triglyceride-rich lipoproteins and LDL compared to monotherapy with
atorvastatin in patients with dyslipidemia secondary to nephrotic syndrome.